Review
Biochemistry & Molecular Biology
Dehua Yang, Qingtong Zhou, Viktorija Labroska, Shanshan Qin, Sanaz Darbalaei, Yiran Wu, Elita Yuliantie, Linshan Xie, Houchao Tao, Jianjun Cheng, Qing Liu, Suwen Zhao, Wenqing Shui, Yi Jiang, Ming-Wei Wang
Summary: Recent progress in understanding the structure-function relationships of G protein-coupled receptors has accelerated drug development significantly. This article aims to provide a comprehensive overview of this important field to a broader readership interested in drug discovery.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2021)
Article
Pharmacology & Pharmacy
Anna Vlachodimou, Henk de Vries, Milena Pasoli, Miranda Goudswaard, Soon-Ai Kim, Yong-Chul Kim, Mirko Scortichini, Melissa Marshall, Joel Linden, Laura H. Heitman, Kenneth A. Jacobson, Adriaan P. IJzerman
Summary: A(2B) adenosine receptor (A(2B)AR) antagonists have therapeutic potential in inflammation-related diseases, but there is a need for novel antagonists. This study investigates the synthesis and biological evaluation of xanthine derivatives as A(2B)AR antagonists. The study finds a clear relationship between a ligand's A(2B)AR residence time and its functional effect, highlighting the importance of binding kinetics in early drug discovery.
BIOCHEMICAL PHARMACOLOGY
(2022)
Review
Pharmacology & Pharmacy
Anh T. N. Nguyen, Diep T. N. Nguyen, Huan Yee Koh, Jason Toskov, William MacLean, Andrew Xu, Daokun Zhang, Geoffrey I. Webb, Lauren T. May, Michelle L. Halls
Summary: The application of artificial intelligence in drug discovery for G protein-coupled receptors (GPCRs) is expanding rapidly. It can assist in understanding the actions of GPCRs, discovering new ligand-GPCR interactions, and predicting clinical responses. This article provides an overview of artificial intelligence concepts and its applications in different stages of GPCR drug discovery. The benefits and limitations of artificial intelligence are discussed, along with the potential for further development in assisting GPCR drug discovery.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Review
Chemistry, Medicinal
Joshua W. Conner, Daniel P. Poole, Manuela Jorg, Nicholas A. Veldhuis
Summary: This review addresses the key challenges, synthesis approaches, and structure-activity relationships in recent fluorescent small molecule studies for GPCRs, and discusses the advantages of using high-resolution GPCR structures to inform conjugation strategies.
FUTURE MEDICINAL CHEMISTRY
(2021)
Article
Neurosciences
Kenneth A. Jacobson, Balaram Pradhan, Zhiwei Wen, Asmita Pramanik
Summary: The discovery and clinical implementation of adenosine, P2Y and P2X receptor modulators have advanced significantly in the past 50 years. Although previous clinical trials of selective ligands have not been successful, there is now a renewed focus on new disease conditions and the development of more selective compounds, as well as the elucidation of new receptor and enzyme structures.
Article
Chemistry, Physical
Daria B. Kokh, Rebecca C. Wade
Summary: The study demonstrates that the tau RAMD approach is able to reproduce relative residence times and reveal dissociation mechanisms effectively, with results consistent with more computationally intensive simulation methods. The simulations accurately predict ligand dissociation rates and changes in residence time due to allosteric modulation.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION
(2021)
Article
Pharmacology & Pharmacy
Harmandeep Kaur, Veera Ganesh Yerra, Sri Nagarjun Batchu, Duc Tin Tran, M. D. Golam Kabir, Youan Liu, Suzanne L. Advani, Phelopater Sedrak, Laurette Geldenhuys, Karthik K. Tennankore, Penelope Poyah, Ferhan S. Siddiqi, Andrew Advani
Summary: In this study, a transcriptional profile of activated kidney fibroblasts and the GPCRs they express was established in mouse models of kidney disease. The marker Tcf21 and the GPCRs Adgra2 and S1pr3 were found to be highly expressed in these activated fibroblasts. This research provides new insights into potential therapeutic targets for treating CKD.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Review
Chemistry, Medicinal
Hyeonyeong Im, Ji-Hyun Park, Seowoo Im, Juhyeong Han, Kyungmin Kim, Yun-Hee Lee
Summary: The high incidence of obesity has led to an increased need to discover new therapeutic targets. Recent research has shown that G-protein coupled receptors (GPCRs) could be potential therapeutic targets to regulate adipose tissue metabolism.
ARCHIVES OF PHARMACAL RESEARCH
(2021)
Review
Pharmacology & Pharmacy
Xuesong Wang, Gerard J. P. van Westen, Laura H. Heitman, Adriaan P. IJzerman
Summary: G protein-coupled receptors (GPCRs) are the largest class of membrane proteins in the human genome, regulating various biological processes and serving as targets for a significant percentage of drugs on the market. Yeast serves as a useful model for studying GPCRs and offers opportunities for novel drug discovery.
BIOCHEMICAL PHARMACOLOGY
(2021)
Article
Multidisciplinary Sciences
Xudong Wang, Chris Neale, Soo-Kyung Kim, William A. Goddard, Libin Ye
Summary: Understanding the roles of intermediate states in GPCR signaling is crucial for studying the activation processes. In this study, conformation-biased mutants were used to enrich the populations of discrete states along the activation pathway of A(2A)R. The results reveal important structural interactions and propose a GPCR activation process modulated by these interactions.
NATURE COMMUNICATIONS
(2023)
Article
Chemistry, Medicinal
Anna Suchankova, Margarita Stampelou, Klontiana Koutsouki, Athanasios Pousias, Lakshiv Dhingra, Kerry Barkan, Nicole Pouli, Panagiotis Marakos, Roxane Tenta, Antonios Kolocouris, Nikolaos Lougiakis, Graham Ladds
Summary: We describe the design and synthesis of pyrazolo[3,4-d]pyridazines as adenosine receptor (AR) ligands. Our results show that the compound 10b, with a 3-phenyl group, a 7-benzylamino group, and a 1-methyl group on the pyrazolopyridazine scaffold, exhibits high affinity for human A(1)R and A(3)R, as well as low toxicity. However, the 2-methyl analog, 15b, does not show significant affinity, possibly due to hindrance of critical hydrogen bonding interactions. This study demonstrates the potential of 10a as a novel scaffold for the development of high affinity AR ligands.
ACS MEDICINAL CHEMISTRY LETTERS
(2022)
Review
Pharmacology & Pharmacy
Bui San Thai, Ling Yeong Chia, Anh T. N. Nguyen, Chengxue Qin, Rebecca H. Ritchie, Dana S. Hutchinson, Andrew Kompa, Paul J. White, Lauren T. May
Summary: Heart failure remains a significant cause of morbidity and mortality worldwide. Current treatment options have limitations, leading to many patients progressing to advanced stages. Exploration of novel therapeutics targeting G protein-coupled receptors (GPCRs) has shown promise, but efficacy and unwanted effects remain as challenges.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Thian-Sze Wong, Guangzhi Li, Shiliang Li, Wei Gao, Geng Chen, Shiyi Gan, Manzhan Zhang, Honglin Li, Song Wu, Yang Du
Summary: Neuropsychiatric disorders are complex and have various causes. Finding effective treatment targets is difficult due to the heterogeneous nature of these diseases. However, the growing knowledge of G protein-coupled receptors (GPCRs) provides a potential avenue for drug discovery. Understanding the molecular mechanisms and structures of GPCRs can aid in the development of effective drugs. This review provides an overview of the role of GPCRs in neurodegenerative and psychiatric diseases, highlights new opportunities for GPCR targets, and discusses recent progress in GPCR drug development.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2023)
Article
Biochemistry & Molecular Biology
Mingcheng Qian, Zhijie Luo, Wenwen Hou, Jingjing Sun, Xin Lu, Qianxi Zhang, Yi Wu, Caile Xue, Shuai Zhao, Xin Chen
Summary: In this study, fourteen new cholic acid derivatives were designed and synthesized, and one of them, B1, was found to be a highly potent TGR5 agonist, which can be used as a lead compound for further study.
BIOORGANIC CHEMISTRY
(2022)
Article
Chemistry, Medicinal
Jieon Lee, Rina Kwag, Soyeon Lee, Doyoung Kim, Jiwan Woo, Yakdol Cho, Hak Joong Kim, Jeongjin Kim, Byungsun Jeon, Hyunah Choo
Summary: The study highlighted the biased agonism of G protein-coupled receptors, identifying a promising G-protein-biased ligand for the treatment of neurodevelopmental and neuropsychiatric disorders. The experimental findings suggest that this drug may have potential efficacy in treating stereotypy in autism spectrum disorders.
JOURNAL OF MEDICINAL CHEMISTRY
(2021)
Article
Pharmacology & Pharmacy
Ahmed Haider, Xiaoyun Deng, Olivia Mastromihalis, Stefanie K. Pfister, Troels E. Jeppesen, Zhiwei Xiao, Vi Pham, Shaofa Sun, Jian Rong, Chunyu Zhao, Jiahui Chen, Yinlong Li, Theresa R. Connors, April T. Davenport, James B. Daunais, Vahid Hosseini, Wenqing Ran, Arthur Christopoulos, Lu Wang, Celine Valant, Steven H. Liang
Summary: This study aimed to develop a suitable M4 PET ligand for the non-invasive visualization of M4 in the brain. The compound 12 was identified as a subtype-selective positive allosteric modulator (PAM) and its radiofluorinated analogue showed moderate specificity in rodent brain sections. However, in non-human primates and humans, the presence of carbachol did not improve the specificity and selectivity of the radioligand.
ACTA PHARMACEUTICA SINICA B
(2023)
Article
Pharmacology & Pharmacy
Ye Jiang, Mahmuda Yeasmin, Arisbel B. Gondin, Arthur Christopoulos, Celine Valant, Wessel A. C. Burger, David M. Thal
Summary: This study investigated the activation of individual G protein subfamilies and downstream signaling pathways of compounds 6A and 7A at the M-2 mAChR. The results showed that M-2 mAChR primarily couples to Galpha(i/o) and Galpha(s), but no Galpha(i) bias was detected for compounds 6A and 7A. This highlights the importance of cellular background in classifying new ligands.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
Ayame Saito, Sadia Alvi, Celine Valant, Arthur Christopoulos, Simona E. Carbone, Daniel P. Poole
Summary: The enteric nervous system plays a crucial role in regulating gastrointestinal motility. Disrupted enteric nervous system activity can lead to dysmotility. Pharmacological treatment options for dysmotility involve targeting G protein-coupled receptors (GPCRs) expressed by enteric nervous system neurons. Current drugs that target GPCRs for motility disorders have drawbacks such as significant side-effects and a loss of physiological tone. Allosteric modulation of GPCRs, which bind to a distinct site from the endogenous ligand, may provide effective relief from motility disorders while minimizing side-effects.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Review
Endocrinology & Metabolism
Brian P. Cary, Xin Zhang, Jianjun Cao, Rachel M. Johnson, Sarah J. Piper, Elliot J. Gerrard, Denise Wootten, Patrick M. Sexton
Summary: G protein-coupled receptors (GPCRs), particularly the B1 class, play a critical role in maintaining homeostasis and are important drug targets. Recent advances in cryo-electron microscopy have provided valuable insights into the structure and dynamics of these receptors, which contribute to our understanding of their functions.
Review
Pharmacology & Pharmacy
Anh T. N. Nguyen, Diep T. N. Nguyen, Huan Yee Koh, Jason Toskov, William MacLean, Andrew Xu, Daokun Zhang, Geoffrey I. Webb, Lauren T. May, Michelle L. Halls
Summary: The application of artificial intelligence in drug discovery for G protein-coupled receptors (GPCRs) is expanding rapidly. It can assist in understanding the actions of GPCRs, discovering new ligand-GPCR interactions, and predicting clinical responses. This article provides an overview of artificial intelligence concepts and its applications in different stages of GPCR drug discovery. The benefits and limitations of artificial intelligence are discussed, along with the potential for further development in assisting GPCR drug discovery.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
Jo-Anne Baltos, Pablo M. Casillas-Espinosa, Ben Rollo, Karen J. Gregory, Paul J. White, Arthur Christopoulos, Patrick Kwan, Terence J. O'Brien, Lauren T. May
Summary: Epilepsy, a serious neurological condition, affects millions of people worldwide. Current pharmacotherapy only successfully controls seizures in about 70% of epilepsy patients, and many suffer from psychiatric and physical comorbidities. Adenosine, a natural substance, has shown potential as an anti-epileptic agent through its receptor activation. Recent advances have also shown that adenosine receptors can modulate epilepsy-associated comorbidities. This review provides an accessible resource on the use of the adenosine system as a therapeutic target for epilepsy and its associated comorbidities.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Review
Pharmacology & Pharmacy
Bui San Thai, Ling Yeong Chia, Anh T. N. Nguyen, Chengxue Qin, Rebecca H. Ritchie, Dana S. Hutchinson, Andrew Kompa, Paul J. White, Lauren T. May
Summary: Heart failure remains a significant cause of morbidity and mortality worldwide. Current treatment options have limitations, leading to many patients progressing to advanced stages. Exploration of novel therapeutics targeting G protein-coupled receptors (GPCRs) has shown promise, but efficacy and unwanted effects remain as challenges.
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Correction
Biochemistry & Molecular Biology
Alexander S. Powers, Vi Pham, Wessel A. C. Burger, Geoff Thompson, Yianni Laloudakis, Nicholas W. Barnes, Patrick M. Sexton, Steven M. Paul, Arthur Christopoulos, David M. Thal, Christian C. Felder, Celine Valant, Ron O. Dror
NATURE CHEMICAL BIOLOGY
(2023)
Article
Biochemistry & Molecular Biology
Alexander S. Powers, Vi Pham, Wessel A. C. Burger, Geoff Thompson, Yianni Laloudakis, Patrick M. Sexton, Steven M. Paul, Arthur Christopoulos, David M. Thal, Christian C. Felder, Celine Valant, Ron O. Dror
Summary: The selectivity of a drug for target receptors is crucial but challenging when the receptors are similar. Serendipitous discovery of ligands that stimulate target receptors more strongly than closely related receptors provides a solution. This study reveals the structural basis for the efficacy-driven selectivity of xanomeline, a clinical drug candidate, between closely related muscarinic acetylcholine receptors (mAChRs), using atomic-level simulations. The results suggest strategies for rational design of ligands achieving efficacy-driven selectivity for G-protein-coupled receptors.
NATURE CHEMICAL BIOLOGY
(2023)
Article
Multidisciplinary Sciences
Wessel A. C. Burger, Vi Pham, Ziva Vuckovic, Alexander S. Powers, Jesse I. Mobbs, Yianni Laloudakis, Alisa Glukhova, Denise Wootten, Andrew B. Tobin, Patrick M. Sexton, Steven M. Paul, Christian C. Felder, Radostin Danev, Ron O. Dror, Arthur Christopoulos, Celine Valant, David M. Thal
Summary: The M4 muscarinic acetylcholine receptor is a significant drug target for the treatment of psychosis, cognition, and addiction. The clinical trial of xanomeline has shown promise in improving symptoms and the cryo-EM structure reveals the binding mechanism, providing insight into its complex pharmacology.
NATURE COMMUNICATIONS
(2023)
Meeting Abstract
Pharmacology & Pharmacy
Celine Valant, Alexander Powers, Vi Pham, Wessel Burger, Emma van der Westhuizen, Nicholas Barnes, Steven Paul, Arthur Christopoulos, David Thal, Christian Felder, Ron Dror
BRITISH JOURNAL OF PHARMACOLOGY
(2023)
Meeting Abstract
Pharmacology & Pharmacy
Huong Thi Mai Nguyen, Emma van der Westhuizen, Elham Khajehali, Arthur Christopoulos, Celine Valant
BRITISH JOURNAL OF PHARMACOLOGY
(2023)